Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05654-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Masahiro Teramoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Haploidentical hematopoietic cell transplantation (HCT) using glucocorticoids for acute graft-versus-host disease prophylaxis (GC-haplo) may become a curative treatment option for nonremission acute myeloid leukemia (AML). This retrospective study aimed to identify pre-HCT predictors of survival in a cohort of 97 nonremission AML treated with GC-haplo in Hyogo Medical University Hospital between 2010 and 2020. Relapse and primary induction failure included in 70 (72%) and 27 (28%) patients, respectively. Sixty-one patients (63%) had undergone previous HCT. Multivariate analysis revealed that ≤ 6 months' duration between first complete remission (CR1) and first relapse (Rel1) (CR1-Rel1 interval) (hazard ratio 2.11, 95% confidence interval [CI] 1.15-3.89, P = 0.016) and serum albumin before starting the conditioning treatment of ≤ 3.5 g/dL (hazard ratio 1.80, 95%CI 1.09-2.96, P = 0.022) as risk factors for overall survival. Among three groups categorized according to serum albumin and CR1-Rel1 interval, the best 3-year overall survival was observed in patients with albumin > 3.5 g/dL and CR1-Rel1 interval > 6 months or primary induction failure (50.2%, 95%CI 28.9%-68.3%, P < 0.001), revealing that survival could be predicted using albumin and past CR duration in patients with very high-risk AML not in remission before GC-haplo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan.
- Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan. tamakhi@hyo-med.ac.jp.
- Department of Hematology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
- First Department of Internal Medicine, Kansai Medical University Medical Center, Moriguchi, Osaka, Japan.
Zitieren
APA
Teramoto, M., Tamaki, H., Kaida, K., Samori, M., Takahashi-Hirata, S., Utsunomiya, N., Katayama, A., Fukunaga, K., Inoue, T., Yoshihara, K., Ikegame, K., Okada, M., & Yoshihara, S. (2024). Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis. Annals of Hematology. https://doi.org/10.1007/s00277-024-05654-7
Vancouver
Teramoto M, Tamaki H, Kaida K, Samori M, Takahashi-Hirata S, Utsunomiya N, et al. Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis. Annals of Hematology. 2024. doi:10.1007/s00277-024-05654-7
BibTeX
@article{Teramoto2024,
author = {Teramoto, Masahiro and Tamaki, Hiroya and Kaida, Katsuji and Samori, Mami and Takahashi-Hirata, Saki and Utsunomiya, Nobuto and Katayama, Atsushi and Fukunaga, Keiko and Inoue, Takayuki and Yoshihara, Kyoko and Ikegame, Kazuhiro and Okada, Masaya and Yoshihara, Satoshi},
title = {Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05654-7}
}
EUVIMED